Quick answers
- What is Aprepitant used for?
- The FDA-approved label (Emend, Merck Sharp & Dohme LLC, July 5, 2024) says: “EMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Aprepitant have a boxed warning?
- No. None of the 7 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Aprepitant?
- The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated April 8, 2026). Ask your pharmacist about alternatives.
- Has Aprepitant been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started December 12, 2025 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Aprepitant?
- 7 companies list prescription products of Aprepitant in the FDA NDC Directory, including Merck Sharp & Dohme LLC, BluePoint Laboratories and Glenmark Pharmaceuticals Inc., USA.
What Aprepitant is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
EMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. …
— FDA label: Emend, Merck Sharp & Dohme LLC, effective July 5, 2024. Read the full label on DailyMed →
The FDA has 7 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 7 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| aprepitant 125 mg capsule | Generic | $112.32 per capsule |
| aprepitant 125 mg powder, for suspension | Brand: Emend | $327.38 per unit |
| aprepitant 40 mg capsule | Generic | $45.11 per capsule |
| aprepitant 80 mg capsule | Generic | $78.69 per capsule |
NADAC list of November 4, 2026; these prices took effect between September 23, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Merck Sharp & Dohme LLC4 products
- BluePoint Laboratories3 products
- Glenmark Pharmaceuticals Inc., USA3 products
- Sandoz Inc3 products
- Torrent Pharmaceuticals Limited3 products
- Golden State Medical Supply, Inc.3 products
- Heron Therapeutics, Inc.2 products
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021549 EMEND | Msd | March 26, 2003 | 21, latest November 14, 2019 2019: Labeling · 2019: Labeling · 2017: Labeling |
| NDA207865 EMEND | Msd Merck Co | December 17, 2015 | 3, latest November 14, 2019 2019: Labeling · 2019: Labeling · 2017: Labeling |
| NDA209296 CINVANTI | Heron Theraps Inc | November 9, 2017 | 4, latest March 5, 2024 2024: Labeling · 2022: Manufacturing (CMC) · 2019: Efficacy |
| NDA216457 APONVIE | Heron Theraps Inc | September 16, 2022 | 1, latest March 5, 2024 2024: Labeling |
Generic approvals (3)
- ANDA090999Sandoz · September 24, 2012
- ANDA207777Glenmark Speclt · October 12, 2017
- ANDA211835Torrent · October 21, 2020
Shortage status
To be discontinued · updated April 8, 2026 · first posted April 8, 2026
| Product | Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03) |
|---|---|
| Company | Merck Sharp & Dohme LLC |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
December 12, 2025 · Class II · Ongoing · D-0241-2026
Presence of particulate matter: potential presence of metal particulates in the product.
Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland — Merck Sharp & Dohme LLC
-
April 13, 2022 · Class II · Terminated · D-1027-2022
cGMP deviations: Temperature abuse
Aprepitant Capsule, USP, 40 mg, 1 capsule per unit dose package, Rx only, MFG: Sandoz Pharma, NDC 0781-2321-06 — Mckesson Medical-Surgical Inc. Corporate Office
-
November 27, 2018 · Class III · Terminated · D-0349-2019
Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.
Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only, Manufactured in India for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430. UPC 368462583401. NDC 68462-583-40 — Glenmark Pharmaceuticals Inc., USA
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Emend, Merck Sharp & Dohme LLC, effective July 5, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →